KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Non Operating Income (2024 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Non Operating Income for 2 consecutive years, with -$12.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 42.43% year-over-year to -$12.4 million, compared with a TTM value of -$73.6 million through Dec 2025, up 12.81%, and an annual FY2025 reading of -$73.6 million, up 12.81% over the prior year.
  • Non Operating Income was -$12.4 million for Q4 2025 at Biocryst Pharmaceuticals, up from -$17.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at -$12.4 million in Q4 2025 and bottomed at -$23.3 million in Q2 2025.